Ring Therapeutics

Ring's platform uses the properties and tissue tropisms of anelloviruses to build viral vectors.

CAMBRIDGE, Mass., — Ring Therapeutics today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

Ring Therapeutics announced preclinical data on its Anellogy platform, describing the potential use of anelloviruses as gene therapy vectors.

Ring Therapeutics published an analysis of anelloviruses in the August 11, 2021 issue of Cell Host & Microbe. The research discusses their potential as an approach to gene therapy.

Anne joined Ring as Executive Director of Program Management in November 2020 and became Vice President in March 2024. She holds an MS in Chemical Engineering from the Norwegian University of Science and Technology and has worked in research and program management in pharma and biotech.

Dean joined Ring Therapeutics as SVP, Finance in November 2021, overseeing finance, accounting, and operations. Previously, Dean held finance roles at eGenesis, Inc. and Proteon Therapeutics.

Kelly joined Ring Therapeutics as SVP and Head of Legal in September 2024. She previously led the legal function at Arbor Biotechnologies and served as IP counsel at Flagship, where she worked on legal structures for biotechnology companies, including Ring Therapeutics.

Ring’s exceptional management team is leading their Anellogy platform in the revolution of programmable medicine.

Ring uses the biology of anelloviruses to develop a platform for programmable medicines.

Ring initially investigated the human commensal virome at Flagship Labs, Flagship Pioneering’s innovation foundry.

Ring Therapeutics is a biotechnology company creating novel vector conjugate medicines that carry more and reach further, expanding possibilities in drug development .